Nicolas Barthelemy has been a Senior Advisor at Mérieux Développement since March 2016. Prior to this, he was the Chief Executive Officer and President of BioTheranostics Inc. - a molecular diagnostics company - from October 2014 to February 2017. He is an accomplished biotechnology Executive and has over 25 years of healthcare industry experience in biopharmaceutical, life sciences and molecular diagnostics across a broad range of functions and company sizes. He served in multiple executive roles at Life Technologies over a nine-year period, last as Chief Commercial Officer. The company was acquired by Thermo Fisher Scientific in February 2014. Prior to Life Technologies, Mr. Barthelemy was with Biogen for eight years, most recently serving as Vice President, Manufacturing. He began his career with Merck & Co., Inc.
Mr. Barthelemy currently serves on the boards of directors of Repligen Corporation (RGEN) and Essen Bioscience.
Mr. Barthelemy received his M.S. in Chemical Engineering from the University of California, Berkeley in 1991 and the equivalent of an M.S. in Chemistry from École Supérieure de Physique et Chimie Industrielles (Paris, France) in 1989 as well as the equivalent of a B.S. in Mathematics, Physics and Chemistry from École Sainte Geneviève (Versailles, France). He also attended Harvard Business School’s Program for Management Development.